Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
1.55-0.03 (-1.90%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1.58
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market Cap419.86M
P/E Ratio (ttm)-1.56
Avg Vol (3m)17,443,050
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals15 days ago

    Investors want to know why Novavax drug trial failed. They'll have to wait.

    Gaithersburg-based Novavax Inc. canceled its highly anticipated annual investors meeting, opting instead to offer promised data on its recently failed RSV vaccine trial during its third quarter earnings call in November. The delay comes after Novavax (NVAX) revealed Sept. 15 that the so-called Resolve trial that the so-called Resolve trial of the company's candidate to treat RSV — a a respiratory virus that infects the lungs and breathing passages — failed to work as expected in older adults. Erck said the company wants to finalize plans before communicating them during the third-quarter call.

  • Novavax, Inc. Imploded and Lost 70% in September -- Is There Any Hope Left?
    Motley Fool19 days ago

    Novavax, Inc. Imploded and Lost 70% in September -- Is There Any Hope Left?

    This is not the RESOLVE that shareholders were looking for from Novavax.

  • GlobeNewswire19 days ago

    Novavax Reschedules 4th Annual Investor and Analyst Meeting

    GAITHERSBURG, Md., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it has rescheduled its 4th annual Investor and Analyst Meeting. The Company will host an Investor and Analyst ...